CDTTW
Conduit Pharmaceuticals Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
2.08
52W High
$0.02
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. is a biopharmaceutical innovator focused on addressing significant unmet medical needs in oncology and autoimmune disorders through its advanced therapies. Leveraging proprietary drug delivery platforms and a robust pipeline of therapeutics, the company is dedicated to translating scientific research into impactful clinical solutions. With a strategic emphasis on collaboration and partnerships, Conduit enhances treatment efficacy while striving to improve patient quality of life. As it progresses through key clinical trial phases, Conduit represents a promising investment opportunity in the dynamic biotech sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.89M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -207.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $83.78 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 57,960 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
224.72%
HV 20-Day
177.29%
HV 30-Day
181.66%
HV 60-Day
162.12%
HV Rank
—
Volatility is currently expanding
Data last updated: 4/10/2026